NewsBenzingaPerspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026 Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026 Benzinga 2026.10.23 14:54 (GMT+0) Open on Benzinga Other news IBM Stock Moves Lower: What's Going On? JP Morgan Maintains Overweight on Itau Unibanco Holding, Lowers Price Target to $9 Amazon’s Big Week: First a New James Bond, Then Anthropic’s IPO JP Morgan Maintains Overweight on Allstate, Lowers Price Target to $291 TELUS Shares Rise After Québecor Submits Unsolicited Acquisition Proposal NVIDIA's Leadership Vacuum Hands AMD Its Biggest Opportunity in Years: Analysts